GlassScriptPhysician profile
Brett B Senor
NPI 1013076587
$2,982.38
in general payments reported to CMS, 2019-2025
26 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $533 · 2023: $924 · 2024: $790 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $649.27 | 2022-2025 | |
| Amgen INC. | $259.99 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $256.94 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $209.58 | 2022-2025 | Eliquis |
| Paratek Pharmaceuticals, INC. | $190.42 | 2022-2024 | Nuzyra |
| Novo Nordisk INC | $172.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $159.01 | 2023-2025 | Arexvy, Shingrix |
| Abbvie INC. | $144.08 | 2022-2023 | Ubrelvy, Vraylar |
| Ibsa Pharma INC. | $114.85 | 2022-2025 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $106.98 | 2022-2024 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.87 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $93.17 | 2023-2024 | Xarelto |
| Abbott Laboratories | $83.60 | 2023-2024 | Octrode, Proclaim |
| Merck Sharp & Dohme LLC | $82.16 | 2022-2024 | Verquvo, Belsomra, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $75.69 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.69 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Specialty L.P. | $34.34 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $30.70 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $29.94 | 2023 | |
| Eisai INC. | $26.74 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $24.40 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.76 | 2025 | |
| Stryker Corporation | $22.12 | 2025 | Clottriever Bold Catheter |
| Astellas Pharma US INC | $18.14 | 2023 | Veozah |
| Regeneron Healthcare Solutions, INC. | $12.82 | 2023 | Evkeeza |
| Irhythm Technologies, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Senor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.